Cargando…

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

PURPOSE: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib has activity in patients with R/R DLBCL but durable responses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roschewski, Mark, Patel, Manish R., Reagan, Patrick M., Saba, Nakhle S., Collins, Graham P., Arkenau, Hendrik-Tobias, de Vos, Sven, Nuttall, Barrett, Acar, Melih, Burke, Kathleen, White, Rafael D., Udriste, Maria, Sharma, Shringi, Dougherty, Brian, Stetson, Daniel, Jenkins, David, Mortlock, Andrew, Forcina, Alessandra, Munugalavadla, Veerendra, Flinn, Ian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472096/ https://www.ncbi.nlm.nih.gov/pubmed/37364001 http://dx.doi.org/10.1158/1078-0432.CCR-22-2483

Ejemplares similares

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
por: Sharma, Shringi, et al.
Publicado: (2022)

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
por: Reilley, Matthew J., et al.
Publicado: (2018)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

Indirect Decompression Failure After Lateral Lumbar Interbody Fusion—Reported Failures and Predictive Factors: Systematic Review
por: Kirnaz, Sertac, et al.
Publicado: (2020)

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
por: Overman, Michael, et al.
Publicado: (2020)

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
por: Taylor, Matthew H., et al.
Publicado: (2022)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
por: Yap, Timothy A., et al.
Publicado: (2021)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
por: Choudhury, Atish D., et al.
Publicado: (2022)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
por: Ring, Alistair, et al.
Publicado: (2023)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
por: Lim, Emerson A., et al.
Publicado: (2022)

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
por: Sharman, Jeff P., et al.
Publicado: (2022)

Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies
por: Edlund, Helena, et al.
Publicado: (2021)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Mind Perception Is the Essence of Morality
por: Gray, Kurt, et al.
Publicado: (2012)

Neuroethics: A New Way of Doing Ethics
por: Levy, Neil
Publicado: (2011)

A Life Worth Giving? The Threshold for Permissible Withdrawal of Life Support From Disabled Newborn Infants
por: Wilkinson, Dominic James
Publicado: (2011)

Just How Cognitive Is “Cognitive Enhancement”? On the Significance of Emotions in University Students' Experiences with Study Drugs
por: Vrecko, Scott
Publicado: (2013)

Troubled sleep: Night waking, breastfeeding and parent–offspring conflict
por: Haig, David
Publicado: (2014)

Thinking Ahead on Deep Brain Stimulation: An Analysis of the Ethical Implications of a Developing Technology
por: Johansson, Veronica, et al.
Publicado: (2014)

Brave New Love: The Threat of High-Tech “Conversion” Therapy and the Bio-Oppression of Sexual Minorities
por: Earp, Brian D., et al.
Publicado: (2014)

Patient and Citizen Participation in Health: The Need for Improved Ethical Support
por: Williamson, Laura
Publicado: (2014)

Ethics of Clinical Science in a Public Health Emergency: Drug Discovery at the Bedside
por: Edwards, Sarah J. L.
Publicado: (2013)

Treating Patients as Persons: A Capabilities Approach to Support Delivery of Person-Centered Care
por: Entwistle, Vikki A., et al.
Publicado: (2013)

The Use of Deception in Public Health Behavioral Intervention Trials: A Case Study of Three Online Alcohol Trials
por: McCambridge, Jim, et al.
Publicado: (2013)

If I Could Just Stop Loving You: Anti-Love Biotechnology and the Ethics of a Chemical Breakup
por: Earp, Brian D., et al.
Publicado: (2013)

A Threat to Autonomy? The Intrusion of Predictive Brain Implants
por: Gilbert, Frederic
Publicado: (2015)

A prospective study of macrophage migration inhibitory factor as a marker of inflammatory detection
por: Zhang, Chao, et al.
Publicado: (2009)

Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework
por: Evitt, Niklaus H., et al.
Publicado: (2015)

Developmental plasticity: Bridging research in evolution and human health
por: Lea, Amanda J, et al.
Publicado: (2018)

The ER membrane protein complex is a transmembrane domain insertase
por: Guna, Alina, et al.
Publicado: (2017)

Why and how to use virtual reality to study human social interaction: The challenges of exploring a new research landscape
por: Pan, Xueni, et al.
Publicado: (2018)

Just Policy? An Ethical Analysis of Early Intervention Policy Guidance
por: Mortimer, Rose, et al.
Publicado: (2018)

Withdrawal Aversion and the Equivalence Test
por: Wilkinson, Dominic, et al.
Publicado: (2019)

Update on the target structures of SARS-CoV-2: A systematic review
por: Prajapat, Manisha, et al.
Publicado: (2020)

When Thinking is Doing: Responsibility for BCI-Mediated Action
por: Rainey, Stephen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b37ul4jm3mdp8339bqn8aerj7c